The U.S. knee reconstruction market exceeded $400 million in the second quarter of 2025, with Zimmer Biomet maintaining a lead but Stryker’s share appears to be growing, according to an Aug. 21 GlobalData news release shared with Becker’s.
Zimmer’s Persona revision system held just over 22% of market share, edging out Stryker’s Triathlon at 21%, which delivered its strongest quarterly revenue since tracking began in 2014. Despite Stryker’s lower pricing, Zimmer has sustained leadership for a decade, aided by the launch of Persona IQ, the first smart implant to capture motion data.
Stryker could take the top spot if sales momentum continues, but Zimmer’s bet on sensor-enabled technology may help preserve its edge. The competition is shifting beyond price toward innovations that deliver measurable recovery and clinical value, according to the release.
